compounded semaglutide banned & Tirzepatide 2025: Safe Use Guide US judge upholds FDA's removal

The ghrelin/GOAT/GHS-R system and energy metabolism

Footnotes Disclaimer/Publishers Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s)

You don't have to keep losing

Retatrutide leverages its unique triple action on GLP-1, GIP, and glucagon receptors to provide lasting weight loss results

Typically, dose escalation begins at 0.25mg weekly and increases incrementally to a maximum of 2.4mg if well-tolerated

Tirzepatide produces greater average weight loss (17.60 kg versus 11.85 kg for semaglutide), and its dual-receptor mechanism provides theoretical advantages for insulin sensitization